|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 2/12/19 Unitedhealth Group Inc 10-K 12/31/18 104:17M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.32M
2: EX-10.1 Material Contract HTML 98K
3: EX-10.26 Material Contract HTML 37K
4: EX-10.50 Material Contract HTML 72K
5: EX-21.1 Subsidiaries List HTML 278K
6: EX-23.1 Consent of Experts or Counsel HTML 31K
7: EX-24.1 Power of Attorney HTML 38K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 45K
9: EX-32.1 Certification -- §906 - SOA'02 HTML 34K
16: R1 Document and Entity Information Document HTML 65K
17: R2 Consolidated Balance Sheets HTML 131K
18: R3 Consolidated Balance Sheet (Parenthetical) HTML 57K
19: R4 Consolidated Statements of Operations HTML 106K
20: R5 Consolidated Statements of Comprehensive Income HTML 75K
21: R6 Consolidated Statements of Changes in Equity HTML 109K
22: R7 Consolidated Statement of Changes in Equity HTML 32K
(Parentheticals)
23: R8 Consolidated Statements of Cash Flows HTML 131K
24: R9 Description of Business (Notes) HTML 31K
25: R10 Basis of Presentation, Uses of Estimates and HTML 94K
Significant Accounting Policies (Notes)
26: R11 Investments (Notes) HTML 217K
27: R12 Fair Value (Notes) HTML 150K
28: R13 Property, Plant, and Capitalized Software (Notes) HTML 53K
29: R14 Goodwill and Intangible Assets (Notes) HTML 114K
30: R15 Medical Costs Payable (Notes) HTML 80K
31: R16 Commercial Paper and Long-Term Debt (Notes) HTML 248K
32: R17 Income Taxes (Notes) HTML 157K
33: R18 Shareholders' Equity (Notes) HTML 49K
34: R19 Share-Based Compensation (Notes) HTML 111K
35: R20 Commitments and Contingencies (Notes) HTML 49K
36: R21 Segment Financial Information (Notes) HTML 307K
37: R22 Quarterly Financial Data (Unaudited) (Notes) HTML 81K
38: R23 Schedule I (Notes) HTML 201K
39: R24 Basis of Presentation, Uses of Estimates and HTML 156K
Significant Accounting Policies (Policies)
40: R25 Fair Value Fair Value (Policies) HTML 43K
41: R26 Schedule I (Policies) HTML 120K
42: R27 Basis of Presentation, Uses of Estimates and HTML 70K
Significant Accounting Policies (Tables)
43: R28 Investments (Tables) HTML 213K
44: R29 Fair Value (Tables) HTML 142K
45: R30 Property, Plant, and Capitalized Software (Tables) HTML 51K
46: R31 Goodwill and Intangible Assets (Tables) HTML 121K
47: R32 Medical Costs Payable (Tables) HTML 82K
48: R33 Commercial Paper and Long-Term Debt (Tables) HTML 250K
49: R34 Income Taxes (Tables) HTML 159K
50: R35 Shareholders' Equity (Tables) HTML 48K
51: R36 Share-Based Compensation (Tables) HTML 114K
52: R37 Commitments and Contingencies (Tables) HTML 40K
53: R38 Segment Financial Information (Tables) HTML 298K
54: R39 Quarterly Financial Data (Unaudited) (Tables) HTML 81K
55: R40 Schedule I (Tables) HTML 207K
56: R41 Basis of Presentation, Uses of Estimates and HTML 89K
Significant Accounting Policies (Details)
57: R42 Basis of Presentation, Uses of Estimates and HTML 42K
Significant Accounting Policies Useful lives for
property, equipment and capitalized software
(Details)
58: R43 Basis of Presentation, Uses of Estimates and HTML 55K
Significant Accounting Policies Redeemable
Noncontrolling Interests (Details)
59: R44 Investments (Narrative) (Details) HTML 42K
60: R45 Investments (Short-Term and Long-Term Investments) HTML 81K
(Details)
61: R46 Investments (Amortized Cost and Fair Value of HTML 103K
Available-for-Sale Debt Securities by Contractual
Maturity) (Details)
62: R47 Investments (Fair Value of Available-For-Sale HTML 66K
Investments with Gross Unrealized Losses by
Investment Type and Length of Time That Individual
Securities Have Been in a Continuous Unrealized
Loss Position) (Details)
63: R48 Fair Value (Narrative) (Details) HTML 39K
64: R49 Fair Value (Financial Assets and Liabilities, HTML 90K
Measured at Fair Value on a Recurring Basis)
(Details)
65: R50 Fair Value (Financial Assets and Liabilities, Not HTML 55K
Measured at Fair Value on a Recurring Basis)
(Details)
66: R51 Property, Plant, and Capitalized Software HTML 35K
(Narrative) (Details)
67: R52 Property, Plant, and Capitalized Software Property HTML 55K
Plant and Equipment Table (Details)
68: R53 Goodwill and Intangible Assets (Narrative) HTML 33K
(Details)
69: R54 Goodwill and Intangible Assets Changes in the HTML 50K
Carrying Amount of Goodwill by Reporting Segment
(Details)
70: R55 Goodwill and Intangible Assets Gross carrying HTML 49K
value, accumulated amortization and net carrying
value of intangible assets (Details)
71: R56 Goodwill and Intangible Assets Weighted-average HTML 42K
useful lives assigned to finite-lived intangible
assets acquired in business combinations (Details)
72: R57 Goodwill and Intangible Assets Amortization HTML 42K
Expense relating to Intangible Assets (Details)
73: R58 Medical Costs Payable (Narrative) (Details) HTML 30K
74: R59 Medical Costs Payable Rollforward (Details) HTML 54K
75: R60 Medical Costs Payable, Incurred and Paid Medical HTML 45K
Cost Development (Details)
76: R61 Commercial Paper and Long-Term Debt (Narrative) HTML 60K
(Details)
77: R62 Commercial Paper and Long-Term Debt (Details) HTML 201K
78: R63 Commercial Paper and Long-Term Debt Maturities of HTML 47K
commercial paper and long-term debt (Details)
79: R64 Income Taxes (Narrative) (Details) HTML 64K
80: R65 Income Taxes Reconciliation of Provision for HTML 48K
Income Taxes (Details)
81: R66 Income Tax Reconciliation of the tax provision at HTML 85K
the U.S. Federal Statutory Rate (Details)
82: R67 Income Taxes Components of Deferred Tax Assets and HTML 83K
Liabilities (Details)
83: R68 Income Taxes Reconciliation of the beginning and HTML 45K
ending amount of unrecognized tax benefits
(Details)
84: R69 Shareholders' Equity (Narrative) (Details) HTML 42K
85: R70 Shareholders' Equity Share Repurchases (Details) HTML 41K
86: R71 Share-Based Compensation (Narrative) (Details) HTML 37K
87: R72 Share-Based Compensation (Stock Option and SAR HTML 79K
Activity) (Details)
88: R73 Share-Based Compensation (Restricted Share HTML 48K
Activity) (Details)
89: R74 Share-Based Compensation Other Share-Based HTML 63K
Compensation Data (Details)
90: R75 Share-Based Compensation (Share-Based Compensation HTML 49K
Principal Fair Value Assumptions) (Details)
91: R76 Commitments and Contingencies (Narrative) HTML 37K
(Details)
92: R77 Commitments and Contingencies Future Lease HTML 47K
Payments (Details)
93: R78 Segment Financial Information (Narrative) HTML 44K
(Details)
94: R79 Segment Financial Information (Details) HTML 124K
95: R80 Quarterly Financial Data (Unaudited) (Details) HTML 69K
96: R81 Schedule I (Details) HTML 42K
97: R82 Schedule I Condensed Balance Sheets (Details) HTML 112K
98: R83 Schedule I Balance Sheet Document (Details) HTML 51K
99: R84 Schedule I Condensed Statement of Comprehensive HTML 72K
Income (Details)
100: R85 Schedule I Statement of Cash Flows (Details) HTML 107K
101: R86 Schedule I Maturities of Commercial Paper and HTML 51K
Long-Term Debt (Details)
103: XML IDEA XML File -- Filing Summary XML 191K
102: EXCEL IDEA Workbook of Financial Reports XLSX 129K
10: EX-101.INS XBRL Instance -- unh-20181231 XML 5.55M
12: EX-101.CAL XBRL Calculations -- unh-20181231_cal XML 302K
13: EX-101.DEF XBRL Definitions -- unh-20181231_def XML 1.41M
14: EX-101.LAB XBRL Labels -- unh-20181231_lab XML 2.33M
15: EX-101.PRE XBRL Presentations -- unh-20181231_pre XML 1.62M
11: EX-101.SCH XBRL Schema -- unh-20181231 XSD 221K
104: ZIP XBRL Zipped Folder -- 0000731766-19-000005-xbrl Zip 400K
| Exhibit |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated
(the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed in this report any change
in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Chief Executive Officer | |
1. | I have reviewed this report on Form 10-K of UnitedHealth Group Incorporated (the “registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d) | Disclosed
in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process,
summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
/s/ JOHN
F. REX | |
John F. Rex Executive Vice President and Chief Financial Officer | |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/12/19 | 3, 4, 8-K | ||
| For Period end: | 12/31/18 | 11-K, 4 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/28/24 UnitedHealth Group Inc. 10-K 12/31/23 119:19M 2/24/23 UnitedHealth Group Inc. 10-K 12/31/22 119:19M |